Myomo, Inc. (MYO) · Insider trading
What Myomo's directors, officers and largest holders bought and sold themselves, from the Form 4 each of them files with the SEC within two business days of a trade. Open-market purchases and sales first: those are the trades somebody chose to make at the market price.
Bought, 12 months
$442,540
4 insiders, 13 trades
Sold, 12 months
$181,391
3 insiders, 0% under a plan
Net, 12 months
+$261,149
bought less sold
Latest filing
2026-10-15
filings read to 2026-10-19
Who traded, two years
| Insider | Bought | Sold | Trades | Last trade | Holds after |
|---|---|---|---|---|---|
| Kirk Thomas FDirector | $643,275 | – | 13 | 2026-06-05 | 693,865 |
| Mitchell MicahChief Commercial Officer | – | $402,877 | 3 | 2026-05-14 | 109,478 |
| Kovelman HarryChief Medical Officer | – | $247,642 | 5 | 2026-09-11 | 89,889 |
| Manko Joseph M. Jr.Director | $173,940 | – | 2 | 2026-05-15 | – |
| Gudonis Paul RDirector, Chief Executive Officer | $144,100 | – | 2 | 2025-08-15 | 1,259,013 |
| Getz Heather CDirector | $65,100 | – | 2 | 2026-03-16 | 131,754 |
| Morris Milton MayoDirector | – | $21,150 | 1 | 2026-09-02 | 208,391 |
| Crowley Thomas Aloysius Jr.Director | $3,216 | – | 2 | 2025-11-19 | – |
Open-market purchases and sales
Newest first. “Plan” marks a trade made under a 10b5-1 plan set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Holds after | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-11 | Kovelman HarryChief Medical Officer | Sale | 15,844 | 1.27 | $20,136 | 89,889 | Form 4/A |
| 2026-09-02 | Morris Milton MayoDirector | Sale | 15,000 | 1.41 | $21,150 | 208,391 | Form 4 |
| 2026-08-20 | Kovelman HarryChief Medical Officer | Sale | 17,500 | 1.73 | $30,275 | 105,733 | Form 4/A |
| 2026-06-05 | Kirk Thomas FDirector | Buy | 40,002 | 1.27 | $50,803 | 693,865 | Form 4 |
| 2026-05-28 | Kirk Thomas FDirector | Buy | 25,000 | 0.99 | $24,750 | 653,863 | Form 4 |
| 2026-05-28 | Kovelman HarryChief Medical Officer | Sale | 11,536 | 1.02 | $11,767 | 108,618 | Form 4 |
| 2026-05-27 | Kovelman HarryChief Medical Officer | Sale | 20,464 | 1.00 | $20,464 | 120,154 | Form 4 |
| 2026-05-18 | Kirk Thomas FDirector | Buy | 43,401 | 0.91 | $39,495 | 628,863 | Form 4 |
| 2026-05-15 | Kirk Thomas FDirector | Buy | 31,605 | 0.91 | $28,761 | 585,462 | Form 4 |
| 2026-05-15 | Manko Joseph M. Jr.Director | Buyindirect | 30,367 | 0.89 | $27,027 | 2,309,775 | Form 4 |
| 2026-05-14 | Mitchell MicahChief Commercial Officer | Sale | 90,231 | 0.86 | $77,599 | 109,478 | Form 4/A |
| 2026-05-14 | Manko Joseph M. Jr.Director | Buyindirect | 170,830 | 0.86 | $146,914 | 2,279,408 | Form 4 |
| 2026-03-16 | Getz Heather CDirector | Buy | 20,000 | 0.70 | $14,000 | 131,754 | Form 4 |
| 2026-03-13 | Kirk Thomas FDirector | Buy | 72,000 | 0.71 | $51,120 | 553,857 | Form 4 |
| 2026-03-12 | Getz Heather CDirector | Buy | 70,000 | 0.73 | $51,100 | 111,754 | Form 4 |
| 2025-11-21 | Kirk Thomas FDirector | Buy | 2,535 | 0.72 | $1,825 | 481,857 | Form 4 |
| 2025-11-20 | Kirk Thomas FDirector | Buy | 4,902 | 0.72 | $3,529 | 479,322 | Form 4 |
| 2025-11-19 | Crowley Thomas Aloysius Jr.Director | Buyindirect | 385 | 0.77 | $296 | 479 | Form 4 |
| 2025-11-18 | Crowley Thomas Aloysius Jr.Director | Buy | 4,000 | 0.73 | $2,920 | 75,748 | Form 4 |
| 2025-08-25 | Kirk Thomas FDirector | Buy | 50,000 | 1.15 | $57,500 | 474,420 | Form 4 |
| 2025-08-18 | Kirk Thomas FDirector | Buy | 50,000 | 1.10 | $55,000 | 424,420 | Form 4 |
| 2025-08-15 | Gudonis Paul RDirector, Chief Executive Officer | Buy | 50,000 | 0.95 | $47,500 | 1,259,013 | Form 4 |
| 2025-05-15 | Gudonis Paul RDirector, Chief Executive Officer | Buy | 30,000 | 3.22 | $96,600 | 1,051,671 | Form 4 |
| 2025-05-15 | Kirk Thomas FDirector | Buy | 36,824 | 3.25 | $119,678 | 344,700 | Form 4 |
| 2025-05-14 | Mitchell MicahChief Commercial Officer | Sale | 90,231 | 0.86 | $77,599 | 109,478 | Form 4 |
| 2025-05-14 | Kirk Thomas FDirector | Buy | 1,943 | 3.25 | $6,315 | 307,876 | Form 4 |
| 2025-05-12 | Kirk Thomas FDirector | Buy | 50,000 | 3.35 | $167,500 | 305,933 | Form 4 |
| 2025-03-14 | Mitchell MicahChief Commercial Officer | Sale | 48,000 | 5.16 | $247,680 | 140,269 | Form 4/A |
| 2025-03-13 | Kirk Thomas FDirector | Buy | 7,400 | 5.00 | $37,000 | 255,933 | Form 4 |
| 2025-03-12 | Kovelman HarryChief Medical Officer | Sale | 30,000 | 5.50 | $165,000 | 97,973 | Form 4 |
Grants, exercises and other transactions
Pay, tax and paperwork rather than a choice to trade at the market price. Two years.
35 × grant or award20 × shares withheld for tax1 × gift1 × option exercise
Show them
| Date | Insider | What | Shares | Price | Holds after | Filing |
|---|---|---|---|---|---|---|
| 2026-10-13 | Gudonis Paul RDirector, Chief Executive Officer | Grant or award A | +71,250 | – | 1,514,292 | Form 4 |
| 2026-10-13 | Henry David AChief Financial Officer | Grant or award A | +51,250 | – | 549,862 | Form 4 |
| 2026-10-13 | Kovelman HarryChief Medical Officer | Grant or award A | +32,500 | – | 122,389 | Form 4 |
| 2026-10-12 | McClure Mary-Katherine HaleChief Commericial Officer | Grant or award A | +275,000 | – | 275,000 | Form 4 |
| 2026-10-12 | Henry David AChief Financial Officer | Shares withheld for tax F | −3,133 | 1.37 | 498,612 | Form 4 |
| 2026-10-09 | Gudonis Paul RDirector, Chief Executive Officer | Grant or award A | +8,363 | – | 1,443,042 | Form 4 |
| 2026-10-09 | Henry David AChief Financial Officer | Grant or award A | +6,272 | – | 501,745 | Form 4 |
| 2026-08-07 | Henry David AChief Financial Officer | Grant or award A | +68,644 | – | 495,473 | Form 4 |
| 2026-08-07 | Henry David AChief Financial Officer | Shares withheld for tax F | −25,310 | 1.42 | 470,163 | Form 4 |
| 2026-08-07 | Gudonis Paul RDirector, Chief Executive Officer | Grant or award A | +146,909 | – | 1,434,679 | Form 4 |
| 2026-08-07 | Mitchell MicahChief Commercial Officer | Grant or award A | +58,409 | – | 152,297 | Form 4 |
| 2026-08-07 | Mitchell MicahChief Commercial Officer | Shares withheld for tax F | −21,559 | 1.42 | 130,738 | Form 4 |
| 2026-08-07 | Kovelman HarryChief Medical Officer | Grant or award A | +55,149 | – | 145,690 | Form 4 |
| 2026-08-07 | Kovelman HarryChief Medical Officer | Shares withheld for tax F | −22,457 | 1.42 | 123,233 | Form 4 |
| 2026-07-13 | Henry David AChief Financial Officer | Shares withheld for tax F | −5,166 | 1.09 | 426,829 | Form 4 |
| 2026-07-10 | Gudonis Paul RDirector, Chief Executive Officer | Grant or award A | +10,454 | – | 1,287,770 | Form 4 |
| 2026-07-10 | Henry David AChief Financial Officer | Grant or award A | +7,840 | – | 431,995 | Form 4 |
| 2026-06-25 | Morris Milton MayoDirector | Grant or award A | +78,704 | – | 223,391 | Form 4 |
| 2026-06-25 | Febbo William JDirector | Grant or award A | +78,704 | – | 123,704 | Form 4 |
| 2026-06-25 | Getz Heather CDirector | Grant or award A | +78,704 | – | 210,458 | Form 4 |
| 2026-06-25 | Kirk Thomas FDirector | Grant or award A | +78,704 | – | 772,569 | Form 4 |
| 2026-06-25 | Crowley Thomas Aloysius Jr.Director | Grant or award A | +78,704 | – | 154,452 | Form 4 |
| 2026-06-25 | Manko Joseph M. Jr.Director | Grant or award A | +78,704 | – | 78,704 | Form 4 |
| 2026-06-12 | Henry David AChief Financial Officer | Shares withheld for tax F | −10,969 | – | 424,155 | Form 4 |
| 2026-06-12 | Mitchell MicahChief Commercial Officer | Shares withheld for tax F | −9,061 | 1.20 | 93,888 | Form 4 |
| 2026-06-12 | Kovelman HarryChief Medical Officer | Shares withheld for tax F | −10,442 | 1.20 | 90,541 | Form 4 |
| 2026-06-08 | Henry David AChief Financial Officer | Shares withheld for tax F | −10,050 | – | 435,124 | Form 4 |
| 2026-06-08 | Kovelman HarryChief Medical Officer | Shares withheld for tax F | −7,635 | 1.33 | 100,983 | Form 4 |
| 2026-06-08 | Mitchell MicahChief Commercial Officer | Shares withheld for tax F | −6,529 | 1.33 | 102,949 | Form 4 |
| 2026-04-14 | Febbo William JDirector | Grant or award A | +45,000 | – | 45,000 | Form 4 |
| 2026-04-13 | Henry David AChief Financial Officer | Shares withheld for tax F | −3,953 | 0.71 | 445,174 | Form 4 |
| 2026-04-10 | Henry David AChief Financial Officer | Grant or award A | +12,500 | – | 449,127 | Form 4 |
| 2026-04-10 | Gudonis Paul RDirector, Chief Executive Officer | Grant or award A | +16,666 | – | 1,277,316 | Form 4/A |
| 2026-01-12 | Henry David AChief Financial Officer | Grant or award A | +8,727 | – | 436,627 | Form 4 |
| 2026-01-12 | Gudonis Paul RDirector, Chief Executive Officer | Grant or award A | +11,637 | – | 1,260,650 | Form 4 |
| 2025-09-09 | Gudonis Paul RDirector, Chief Executive Officer | Gift G | −10,000 | – | 1,249,013 | Form 4 |
| 2025-06-30 | Henry David AChief Financial Officer | Shares withheld for tax F | −23,587 | 2.19 | 427,900 | Form 4 |
| 2025-06-30 | Kovelman HarryChief Medical Officer | Shares withheld for tax F | −13,054 | 2.19 | 140,618 | Form 4 |
| 2025-06-11 | Gudonis Paul RDirector, Chief Executive Officer | Grant or award A | +157,342 | – | 1,209,013 | Form 4 |
| 2025-06-11 | Henry David AChief Financial Officer | Grant or award A | +76,398 | – | 451,487 | Form 4 |
| 2025-06-11 | Mitchell MicahChief Commercial Officer | Grant or award A | +59,440 | – | 199,709 | Form 4 |
| 2025-06-11 | Kovelman HarryChief Medical Officer | Grant or award A | +62,938 | – | 153,672 | Form 4 |
| 2025-06-11 | Getz Heather CDirector | Grant or award A | +29,720 | – | 41,754 | Form 4 |
| 2025-06-11 | Morris Milton MayoDirector | Grant or award A | +29,720 | – | 144,687 | Form 4 |
| 2025-06-11 | Crowley Thomas Aloysius Jr.Director | Grant or award A | +29,720 | – | 71,748 | Form 4 |
| 2025-06-11 | Kirk Thomas FDirector | Grant or award A | +29,720 | – | 374,420 | Form 4 |
| 2025-06-06 | Henry David AChief Financial Officer | Shares withheld for tax F | −8,373 | 2.97 | 375,089 | Form 4 |
| 2025-06-06 | Kovelman HarryChief Medical Officer | Shares withheld for tax F | −5,743 | 2.97 | 90,734 | Form 4 |
| 2025-03-13 | Mitchell MicahChief Commercial Officer | Shares withheld for tax F | −1,283 | 5.22 | 188,572 | Form 4/A |
| 2025-03-13 | Henry David AChief Financial Officer | Shares withheld for tax F | −2,019 | 5.22 | 383,462 | Form 4 |
| 2025-03-13 | Kovelman HarryChief Medical Officer | Shares withheld for tax F | −1,496 | 5.22 | 96,477 | Form 4 |
| 2025-03-11 | Mitchell MicahChief Commercial Officer | Grant or award A | +3,737 | – | 189,855 | Form 4/A |
| 2025-03-11 | Henry David AChief Financial Officer | Grant or award A | +4,106 | – | 385,481 | Form 4 |
| 2025-03-11 | Gudonis Paul RDirector, Chief Executive Officer | Grant or award A | +6,708 | – | 1,021,671 | Form 4 |
| 2025-03-11 | Kovelman HarryChief Medical Officer | Grant or award A | +3,553 | – | 127,973 | Form 4 |
| 2025-02-13 | Gudonis Paul RDirector, Chief Executive Officer | Option exercise M | +694 | 0.05 | 1,014,963 | Form 4 |
| 2024-11-04 | Kovelman HarryChief Medical Officer | Shares withheld for tax F | −121 | 3.70 | 123,314 | Form 4 |
How to read it
- Buy, sale
- Code P and S on the form: shares bought or sold in the market, at the market price. The other codes are mostly pay (a grant, an option exercised) or tax (shares the company withheld), and say little about what the insider thinks of the price.
- Plan
- A sale or purchase under a Rule 10b5-1 plan, set up in advance and running on its own schedule. Since April 2023 the form has a box for it. Much executive selling is planned and says more about diversifying than about the company.
- Holds after
- The shares the insider still held after the trade, in the form the trade was in (directly, or indirectly through a trust or a fund).
- Value
- Shares times the price the form reports, which is often an average over several fills on the day.
Read from the SEC's own quarterly data sets of Forms 3, 4 and 5, and from each day's filings since the last one. A correcting amendment replaces the lines it restates. Every row links to its filing. None of this is advice: insiders sell for many reasons, and buy for fewer.